Knee Osteoarthritis: Clinical and MRI Outcomes After Multiple Intra-Articular Injections With Expanded Autologous Adipose-Derived Stromal Cells or Platelet-Rich Plasma

Cartilage. 2023 Dec;14(4):433-444. doi: 10.1177/19476035231166127. Epub 2023 Jun 22.

Abstract

Objective: To directly compare clinical and MRI outcomes of multiple intra-articular injections of adipose-derived stromal cells (ASCs) or platelet-rich plasma (PRP) in patients with knee osteoarthritis (OA).

Design: We retrospectively compared 24-month outcomes in (1) 27 patients receiving 3-monthly intra-articular injections with a total of 43.8 million ASCs and (2) 23 patients receiving 3-monthly injections of 3-ml preparation of PRP. All patients had Kellgren-Lawrence grade 1, 2, or 3 knee OA with failed conservative medical therapy. The Numeric Pain Rating Scale (NPRS) scores; Knee injury and Osteoarthritis Outcome Score (KOOS) at baseline, 6, 12, and 24 months after the first injection; and the MRI Osteoarthritis Knee Score (MOAKS) at 12 and 24 months were considered as outcomes.

Results: No major complications occurred in any patient. Both groups significantly improved in pain NPRS score and KOOS at 6 months. At 12- and 24-month evaluations, the ASC group significantly decreased scores to a greater degree (P < 0.001) than the PRP group. MOAKS scores indicated a decrease in disease progression in the ASC group.

Conclusion: Both ASCs and PRP were safe and resulted in clinical improvement in patients with knee OA at 6 months; however, at 12 and 24 months, ASCs outperformed leukocyte-poor PRP in clinical and radiological outcomes.

Keywords: adipose-derived stromal cells; cartilage injury; intra-articular injection; osteoarthritic knee pain; stem cells.

MeSH terms

  • Humans
  • Injections, Intra-Articular
  • Magnetic Resonance Imaging
  • Osteoarthritis, Knee* / drug therapy
  • Osteoarthritis, Knee* / therapy
  • Pain / drug therapy
  • Platelet-Rich Plasma*
  • Retrospective Studies
  • Stromal Cells
  • Treatment Outcome